|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0100 CAD | -.--% |
|
-.--% | -83.33% |
| Market Cap | 1.19M 849K 737K 687K 631K 80.74M 1.21M 8.1M 3.17M 40.36M 3.19M 3.12M 134M | P/E 2024 |
-0.07x | P/E 2025 | -0.2x |
|---|---|---|---|---|---|
| Enterprise Value | 470K 334K 290K 271K 249K 31.81M 476K 3.19M 1.25M 15.9M 1.26M 1.23M 52.69M | EV / Sales 2024 |
0.13x | EV / Sales 2025 | 0.32x |
| Free-Float |
68.57% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -33.33% | ||
| 6 months | -71.43% | ||
| Current year | -83.33% |
| 1 month | 0 | 0.01 | |
| Current year | 0 | 0.05 | |
| 1 year | 0 | 0.25 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.8 | |
| 10 years | 0 | 1.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jackie Burnett
CEO | Chief Executive Officer | - | 30/09/2019 |
José Roldan
DFI | Director of Finance/CFO | - | 08/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Jackie Burnett
BRD | Director/Board Member | - | 30/09/2019 |
Daniel Augereau
BRD | Director/Board Member | 82 | 30/09/2019 |
Eric Klein
BRD | Director/Board Member | 66 | 30/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/06/25 | Sell | Chief Executive Officer | 4,667,000 | 3.9091% | ||
| 21/03/25 | Buy | Chief Executive Officer | 200,000 | 0.1675% | ||
| 21/03/25 | Buy | Chief Executive Officer | 100,000 | 0.0838% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -.--% | -80.00% | 850K | ||
| +0.95% | -7.71% | +46.49% | +150.62% | 1T | ||
| -0.44% | -5.18% | +47.87% | +49.62% | 613B | ||
| -0.65% | -7.57% | +23.37% | +64.68% | 433B | ||
| +0.48% | -2.77% | +40.27% | +34.96% | 350B | ||
| +0.08% | -4.45% | +31.74% | +39.89% | 292B | ||
| +2.09% | -9.27% | +5.42% | +7.61% | 239B | ||
| +1.75% | -8.29% | -1.73% | -42.05% | 206B | ||
| +2.12% | -1.68% | +28.00% | +58.86% | 204B | ||
| +0.25% | -2.39% | +14.50% | +66.64% | 163B | ||
| Average | +0.72% | -3.49% | +23.59% | +35.08% | 350.05B | |
| Weighted average by Cap. | +0.61% | -4.34% | +33.81% | +71.13% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.34M 3.09M 2.68M 2.5M 2.3M 294M 4.39M 29.46M 11.52M 147M 11.59M 11.34M 486M | 3.36M 2.39M 2.07M 1.93M 1.78M 227M 3.4M 22.8M 8.91M 114M 8.97M 8.78M 376M |
| Net income | -16.5M -11.73M -10.19M -9.5M -8.73M -1.12B -16.68M -112M -43.78M -558M -44.06M -43.09M -1.85B | -8.91M -6.33M -5.5M -5.13M -4.71M -603M -9.01M -60.46M -23.64M -301M -23.79M -23.27M -998M |
| Net Debt | -626K -445K -386K -360K -331K -42.32M -633K -4.25M -1.66M -21.15M -1.67M -1.63M -70.09M | -723K -514K -447K -416K -383K -48.93M -731K -4.91M -1.92M -24.46M -1.93M -1.89M -81.04M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- RAMM Stock
Select your edition
All financial news and data tailored to specific country editions
















